About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

No Longer AvailableNCT03196934

Expanded Use of Cannabidiol Oral Solution

To allow subjects who have completed Insys 030 extension study to continue to take Cannabidiol oral solution.

Lead sponsor: MultiCare Health System Research Institute•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

MultiCare Health System Research Institute

To allow subjects who have completed Insys 030 extension study (A multicenter, open-label, flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure disorder who complete INS011-14-029 or Part A of INS011-15-054) to continue to take Cannabidiol oral solution.

Age

1 - 18 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Completed the Insys 030 protocol
•2. Compliant in drug study procedures
•3. Non-pregnant females of child bearing age, willing to utilize a double-barrier method of birth control during treatment and for 30 days after treatment has ended

Exclusion Criteria

•1. Failure to follow study procedures in Insys 030
•2. Pregnant females

Related studies

Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application

NCT06425029 · Epilepsy, Refractory Epilepsy, and more

Model-based Electrical Brain Stimulation

NCT05327387 · Medication Refractory Epilepsy Patients With Electrodes Already Implanted Based on Clinical Criteria for Standard Monitoring

Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy

NCT06304389 · Refractory Epilepsy

RECRUITINGPhase 2

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

NCT05019885 · Drug Resistant Epilepsy, Medically Refractory Epilepsy, and more

Optimal Stimulation Parameters to Disrupt Epileptiform Activity

NCT06141668 · Refractory Epilepsy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 2, 2024Terms

Trial snapshot

StatusNO_LONGER_AVAILABLE

Phase—

Enrollment—

Start date—

Last updatedFeb 2, 2024

Condition

Refractory Epilepsy

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions